WO2005092898A1 - Conjugue d'extraits de tripterydium a polymere hydrophile et leurs compositions pharmaceutiques - Google Patents
Conjugue d'extraits de tripterydium a polymere hydrophile et leurs compositions pharmaceutiques Download PDFInfo
- Publication number
- WO2005092898A1 WO2005092898A1 PCT/CN2005/000298 CN2005000298W WO2005092898A1 WO 2005092898 A1 WO2005092898 A1 WO 2005092898A1 CN 2005000298 W CN2005000298 W CN 2005000298W WO 2005092898 A1 WO2005092898 A1 WO 2005092898A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triptolide
- group
- polyethylene glycol
- conjugate according
- ester
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
Definitions
- the present invention relates to a combination of a hydrophilic polymer and a tripterygium wilfordii extract or a derivative thereof, and a pharmaceutical composition comprising the combination.
- Tripterygium wilfordii is also called yellow rattan, belonging to the genus Euonymus.
- Fujian firstly used Tripterygium wilfordii to treat leprosy and rheumatoid arthritis, and obtained satisfactory results.
- Tripterygium wilfordii also has a certain effect on the infection caused by cancer and organ transplantation.
- Tripterygium wilfordii The constituents of Tripterygium wilfordii are complex, and its active ingredients are: triptolide, tripdiolide, triptonide, hypolide methyl ether, and triptolide Triptonolide, tripcheorolide, triptriolide, wilforonide, tripterygine, tripterygine, wilfordine, tripterol Wilforgine, wilforine, wilfortrine, wilforzine, wilfordic acid, hydroxy wilfordic acid, wilfordine (Tripterin or celustrol), tripterygium glycosides, etc.
- Triptolide and betaine both have obvious antitumor activity.
- tripterygium wilfordii Animal experiments show that the most sensitive target organs for the toxicity of tripterygium wilfordii are the gastrointestinal system, hematopoietic system, and reproductive system. The digestive tract reaction is the most common. Rat testicular reproductive epithelium is degenerative, spermatogonia cell division is inhibited, and spermatogenic cells at all levels decrease and disappear. A large number of studies have shown that triptolide is its main active ingredient and also a major toxic ingredient, and the effective dose is almost equivalent to the toxic dose, which greatly hinders the further popularization of the Chinese medicine triptolide.
- PEG and its derivatives are used as Carriers for pharmaceutical preparations have been widely used in many commercial drugs, and attempts to bond PEG to drug molecules have also made great progress in the past decade, and are widely used in many approved drugs, such as PEG -intron® and PEGasys®, the bond of ⁇ -interferon and polyethylene glycol show longer circulating half-life and better therapeutic effect.
- Paclitaxel and polyethylene glycol linkages have correspondingly reduced toxicity and prolonged biological activity. The metabolic process of polyethylene glycol in the human body is quite clear, and it is a safe, no side effect drug modifier.
- the object of the present invention is to combine the hydrophilic polymer with the tripterygium wilfordii extract by a similar method, thereby increasing the solubility of the tripterygium wilfordii extract, reducing its toxicity, and extending the cycle of the tripterygium wilfordii extract in the organism Half-life to ensure proper drug concentration and provide sustained release.
- P is a water-soluble polymer, and is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyamino acids, polypropylene morpholine, and copolymers thereof; n is an integer that does not exceed a terminal on P at most Number of active functional groups;
- L is a linking group selected from the group consisting of an ester group, a carbonate group, an amide group, an amide ester group, an ether group, an amine group, and a urethane group;
- the extract of Tripterygium wilfordii includes but is not limited to: triptolide, tripdiolide, triptonide, hypolide methyl ether) ⁇ triptonolide, tripcheorolide, triptriolide, wilforonide, tripterygine, triptolide (wilfordine), tripterine (wilforgine), tripterine (wilforine), tripterine (wilfortrine), tripterine (wilforzine), tripterylic acid (wilfordic acid), hydroxy tripterine (hydroxy triptolide) wilfordic acid), tripterin or celustrol, and triptoside.
- the water-soluble polymer is preferably polyethylene glycol or a copolymer thereof.
- the conjugate is a hydrophilic polymer-triptolide conjugate represented by the following general formula:
- P represents a water-soluble polymer, preferably polyethylene glycol or a copolymer thereof; ⁇ is an integer, and the maximum number does not exceed the number of terminal functional groups on P;
- L is a linking group that connects the triptolide extract with the end-active functional group of the water-soluble polymer, preferably but not limited to: ester group, carbonate group, amide group, amide ester group, ether group, amine group, amino acid ester group .
- a hydrophilic polymer represented by the general formula (II), a polycarboxy oligopeptide, and a triptolide extract or a derivative thereof is provided:
- P is a hydrophilic polymer, selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyamino acids, polypropylene morpholine, and copolymers thereof; m is an integer from 2 to 12; j is 1 An integer of 6
- Ri is a group selected from the group consisting of H, d- 12 alkyl, substituted aryl, arylfluorenyl, heterofluorenyl, and substituted fluorenyl;
- X is a linking group, selected from 0 (CH 2 ); tCO, 0 (CH 2 ) k OCO, 0 (CH 2 ) * NHCO, NR (CH 2 ) k OCO, NR (CH 2 ) NHCO, NR (CH 2 ) a group consisting of * CO, where A: is an integer from 1 to 6;
- Z is a linking group selected from the group consisting of an ester group, a carbonate group, an amide group, an amide ester group, an ether group, an amine group, a urethane group, and an amino acid amide group;
- D is a tripterygium wilfordii extract or a derivative thereof, preferably triptolide. According to another aspect of the present invention, it provides a pharmaceutical composition comprising the above-mentioned conjugate.
- An advantage of the present invention is that the modified drug of the hydrophilic polymer can provide protection to the drug bound to the Tripterygium wilfordii extract, improve its stability and water solubility, reduce toxicity, and prolong the activity of the active extract of Tripterygium wilfordii in biological The circulation half-life in the body ensures proper drug concentration and provides a sustained release function.
- the conjugate of the present invention can be prepared as follows: The hydrophilic polymer is modified, active functional groups are introduced, and then the active group (such as the hydroxyl group on triptolide) is combined with the triptolide extract.
- An example of polyethylene glycol as a hydrophilic polymer will now be described. It should be understood that the water-soluble polymer of the present invention is not limited to polyethylene glycol or a copolymer thereof, and for example, polypropylene glycol, polyvinyl alcohol, polyamino acids, polypropylene morpholine, and copolymers thereof can also be used.
- the structural formula of polyethylene glycol (PEG) can be shown in (III):
- R is H or C ⁇ z ⁇ group
- R is lower fluorenyl
- R may be any lower alkyl group containing 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl Or n-hexyl.
- R is a cycloalkyl group
- R is preferably a cyclofluorenyl group having 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, and cyclohexyl.
- a preferred cycloalkyl is cyclohexyl.
- R is most preferably methyl, ie the compound formed is methoxypolyethylene glycol (mPEG).
- mPEG methoxypolyethylene glycol
- branched or other structured polyethylene glycols can also be used in this invention.
- Y-shaped branch, U-shaped branch, star-shaped and multi-branched polyethylene glycol, etc. can also be used to modify the molecular structure of tripterygium wilfordii extract.
- polyethylene glycol the molecular weight is generally used. As long as the molecular weight of the polyethylene glycol forming the conjugate is 150 to 60,000 Daltons, this is equivalent to / about 3 to 1,300.
- / is 28, 112, 225, and 450, which correspond to molecular weights of 1325, 5000, 10,000, and 20,000, respectively. Due to the potential heterogeneity of the starting PEG compound, which is usually defined by its average molecular weight rather than by self-repeating units, it is preferred to characterize the polyethylene glycol polymer by molecular weight rather than the integer / representing self-repeating units in the PEG polymer.
- Various molecular weight starting PEG compounds can be prepared by methods known in the art or can be obtained from commercial sources.
- the extract of Tripterygium wilfordii includes but is not limited to: triptolide, tripdiolide, triptonide, hypolide methyl ether) triptonolide, tripcheorolide, triptriolide, wilforonide, tripterygine, triptolide (wilfordine), tripterine (wilforgine), tripterine (wilforine), tripterine (wilfortrine), tripterine (wilforzine), tripterylic acid (wilfordic acid), hydroxy tripterine (hydroxy triptolide) wilfordic acid), tripterin or celustrol, and triptoside.
- Their chemical structures are as follows:
- Tripdiolide contains hydroxyl groups in these structures, and can be combined with polymers that have been modified by end groups through methods such as ester groups, carbonate groups, and amide ester groups to achieve effective protection and reasonable drug molecules. use.
- the ester group can release a pharmaceutically active ingredient in a biologically degradable manner.
- the hydrophilic polymer- Tripterygium wilfordii extract conjugate of the present invention can be administered in the form of a pure compound or a suitable pharmaceutical composition, and can also be performed in any acceptable manner of administration or an agent for similar purposes. Therefore, another aspect of the present invention is to provide a pharmaceutical composition comprising the conjugate.
- the method of administration can be selected through oral, intranasal, rectal, transdermal or injection.
- the form of administration is solid, semi-solid, lyophilized powder or liquid medicine, such as tablets, suppositories, pills, Soft and hard gelatin Capsules, powders, solutions, suspensions or aerosols, etc. are preferably in unit dosage form suitable for simple administration of precise doses.
- the composition may include a conventional pharmaceutical carrier or excipient and the conjugate of the present invention as an active ingredient (one or more), and may further include other agents, carriers, adjuvants, and the like.
- a pharmaceutically acceptable composition will contain from about 1 to about 99% by weight of a conjugate of the invention, and from 99 to 1% by weight of a suitable pharmaceutical excipient.
- the composition comprises from about 5 to 75% by weight of a conjugate of the invention, the balance being suitable pharmaceutical excipients.
- the preferred route of administration is by injection, using a conventional daily dosage regimen that can be adjusted according to the severity of the disease.
- the combination of the present invention or a pharmaceutically acceptable salt thereof can also be formulated as an injectable, for example, using about 0.5 to about 50% of the active ingredient dispersed in a pharmaceutical adjuvant that can be administered in liquid form, an example being water , Saline, aqueous glucose, glycerol, ethanol, etc., thereby forming a solution or suspension.
- the pharmaceutical composition that can be administered in liquid form can be dissolved and dispersed in a carrier by dissolving or dispersing the conjugate of the present invention (about 0.5 to about 20%) and a selective pharmaceutical adjuvant.
- a carrier by dissolving or dispersing the conjugate of the present invention (about 0.5 to about 20%) and a selective pharmaceutical adjuvant.
- examples are water, saline, aqueous dextrose, glycerol, ethanol, etc. to form a solution or suspension.
- the pharmaceutical composition of the present invention may also contain a small amount of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, antioxidants, etc., such as: citric acid, sorbitan monolaurate, triethanolamine oil Acid esters, butylated hydroxytoluene, and the like.
- triptolide 100 mg triptolide, 1.0 g of methoxypolyethylene glycol acetic acid (Mw5000), 36 mg of 4-dimethylaminopyridine dissolved in 15 ml of anhydrous dichloromethane, and 80 mg of dicyclohexylcarbodicarbonate Imine. The solution was stirred at room temperature overnight. The precipitate was removed by filtration, and the solution was concentrated. The residue was added with 15 ml of isopropanol and 30 ml of diethyl ether, washed with filtration, and the product was dried under vacuum. Triptolide-14-methoxy polyethylene glycol acetate (1) was obtained. Yield: 0.9 g. Melting point: 55—57 ° C.
- triptolide 100 mg triptolide, 1.0 g polyethylene glycol diacetate (MwlOOOO), 36 mg 4-dimethylaminopyridine dissolved in 15 ml of anhydrous dichloroformamidine, and 80 mg of dicyclohexylcarbodiimide added amine. The solution was stirred at room temperature overnight. The precipitate was removed by filtration, and the solution was concentrated. The residue was added with 15 ml of isopropanol and 30 ml of diethyl ether, washed by filtration, and the product was dried under vacuum. Triptolide-14-polyethylene glycol acetate diester (2) was obtained. Yield: 0.9 g. Melting point-57_59 ° C.
- Example 8 Preparation of a lyophilized powder injection of a conjugate of the present invention This example illustrates the preparation of a representative parenteral pharmaceutical composition, which composition comprises the conjugate of the present invention.
- Example 5 0.9% saline solution to 100 ml.
- the conjugate of Example 5 was dissolved in 0.9% saline solution to obtain 100 ml of a solution for intravenous injection, which was filtered through a 0.2 ⁇ m membrane filter material, frozen, dried under Packaging to obtain lyophilized powder injection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100296153A CN100374443C (zh) | 2004-03-29 | 2004-03-29 | 亲水性聚合物-雷公藤提取物的结合物及其药物组合物 |
CN200410029615.3 | 2004-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092898A1 true WO2005092898A1 (fr) | 2005-10-06 |
Family
ID=35049288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/000298 WO2005092898A1 (fr) | 2004-03-29 | 2005-03-11 | Conjugue d'extraits de tripterydium a polymere hydrophile et leurs compositions pharmaceutiques |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100374443C (zh) |
WO (1) | WO2005092898A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012516899A (ja) * | 2009-02-05 | 2012-07-26 | ファーマジェネシス, インコーポレイテッド | 抗癌剤および免疫調節因子としてのトリプトリドc環誘導体 |
US20150359900A1 (en) * | 2013-01-28 | 2015-12-17 | Jenkem Technology Co. Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US20160271116A1 (en) * | 2013-12-02 | 2016-09-22 | Jenkem Technology Co., Ltd. | Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives |
CN115154451A (zh) * | 2022-07-12 | 2022-10-11 | 湖南农业大学 | 一种预防钩吻生物碱葫蔓藤碱丁中毒的药物 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100411609C (zh) * | 2006-11-27 | 2008-08-20 | 西北农林科技大学 | 一种雷公藤多甙纳米乳药物及其制备方法 |
CN102432866B (zh) * | 2011-09-20 | 2013-10-30 | 同济大学 | 一种雷公藤甲素前药的制备方法 |
CN103965458B (zh) * | 2013-01-28 | 2017-02-15 | 天津键凯科技有限公司 | 聚乙二醇‑氨基酸寡肽‑达沙替尼结合物及其药物组合物 |
CN104548120A (zh) * | 2013-10-22 | 2015-04-29 | 北京林业大学 | 聚乙二醇-白桦脂酸结合物及其制备方法 |
CN105121455B (zh) * | 2013-12-11 | 2017-06-16 | 香港浸会大学 | 新的雷公藤甲素衍生物及其制备方法和用途 |
CN103816548A (zh) * | 2014-03-11 | 2014-05-28 | 北京林业大学 | 靶向亲水性聚合物-雷公藤甲素结合物 |
CN106619765B (zh) * | 2017-01-20 | 2020-02-07 | 浙江省人民医院 | 一种含有乌骨藤提取物的药物组合物 |
CN107137720A (zh) * | 2017-04-29 | 2017-09-08 | 北京林业大学 | 一种新型包载雷公藤甲素和羟基喜树碱的多臂聚乙二醇纳米药物的制备方法 |
CN106924220A (zh) * | 2017-04-29 | 2017-07-07 | 北京林业大学 | 一种肿瘤靶向多臂聚乙二醇‑雷公藤甲素纳米药物的制备 |
CN109701030A (zh) * | 2017-10-26 | 2019-05-03 | 湖南华腾制药有限公司 | 聚乙二醇化小分子药物的制备方法 |
CN110652596B (zh) * | 2019-11-06 | 2020-11-03 | 吉林大学 | 一种雷公藤红素纳米粒子、其制备方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1283643A (zh) * | 2000-07-05 | 2001-02-14 | 天津大学 | 聚乙二醇支载的紫杉醇或多烯紫杉醇的前药 |
CN1442440A (zh) * | 2002-03-05 | 2003-09-17 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
CN1446838A (zh) * | 2002-03-22 | 2003-10-08 | 北京键凯科技有限公司 | 亲水性聚合物—水飞蓟提取物的结合物以及包含该结合物的药物组合物 |
CN1448420A (zh) * | 2002-04-01 | 2003-10-15 | 北京键凯科技有限公司 | 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物 |
-
2004
- 2004-03-29 CN CNB2004100296153A patent/CN100374443C/zh not_active Expired - Fee Related
-
2005
- 2005-03-11 WO PCT/CN2005/000298 patent/WO2005092898A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1283643A (zh) * | 2000-07-05 | 2001-02-14 | 天津大学 | 聚乙二醇支载的紫杉醇或多烯紫杉醇的前药 |
CN1442440A (zh) * | 2002-03-05 | 2003-09-17 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
CN1446838A (zh) * | 2002-03-22 | 2003-10-08 | 北京键凯科技有限公司 | 亲水性聚合物—水飞蓟提取物的结合物以及包含该结合物的药物组合物 |
CN1448420A (zh) * | 2002-04-01 | 2003-10-15 | 北京键凯科技有限公司 | 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012516899A (ja) * | 2009-02-05 | 2012-07-26 | ファーマジェネシス, インコーポレイテッド | 抗癌剤および免疫調節因子としてのトリプトリドc環誘導体 |
US20150359900A1 (en) * | 2013-01-28 | 2015-12-17 | Jenkem Technology Co. Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US9700633B2 (en) * | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US20160271116A1 (en) * | 2013-12-02 | 2016-09-22 | Jenkem Technology Co., Ltd. | Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives |
US10098870B2 (en) * | 2013-12-02 | 2018-10-16 | Jenkem Technology Co., Ltd. (Beijing) | Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives |
CN115154451A (zh) * | 2022-07-12 | 2022-10-11 | 湖南农业大学 | 一种预防钩吻生物碱葫蔓藤碱丁中毒的药物 |
CN115154451B (zh) * | 2022-07-12 | 2023-10-13 | 湖南农业大学 | 一种预防钩吻生物碱葫蔓藤碱丁中毒的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN1676525A (zh) | 2005-10-05 |
CN100374443C (zh) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005092898A1 (fr) | Conjugue d'extraits de tripterydium a polymere hydrophile et leurs compositions pharmaceutiques | |
US7498035B2 (en) | Compounds of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicines | |
WO2005121181A1 (fr) | Polyethyleneglycol-oligopeptides de type branchement d'arbre multipoint et leurs derives actifs et composes | |
JP4272537B2 (ja) | Y型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物 | |
JP4860813B2 (ja) | 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート | |
US10098870B2 (en) | Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives | |
WO2013067767A1 (zh) | 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物 | |
US20050220753A1 (en) | Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them | |
WO2005044837A1 (fr) | Conjugues d'extraits de buxus et de polymere hydrophile et compositions pharmaceutiques correspondantes | |
CN102336904A (zh) | 一种喜树碱及其衍生物的多价peg修饰物及其用途 | |
CN113995846B (zh) | 聚乙二醇偶联药物增效剂、其制备方法及用途 | |
US20240115713A1 (en) | Polyethylene glycol conjugate drug, and preparation method therefor and use thereof | |
CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
US20060014666A1 (en) | Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders | |
CN1318426C (zh) | 新型的斑蝥胺和去甲斑蝥胺衍生物及其在医药中的应用 | |
JP2009539879A (ja) | インデノイソキノリン放出性ポリマー複合体 | |
CN102188716B (zh) | 以氨基酸或寡肽为连接子的大分子-长春碱偶合物 | |
CN1556801A (zh) | 亲水性聚合物-黄酮结合物以及包含该结合物的药物组合物 | |
JPH05320118A (ja) | 新規スパガリン関連化合物及びその用途 | |
JPH01117830A (ja) | 抗サイトメガロウイルス剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |